Results 1 to 10 of about 4,308 (211)

Hormonal Contraceptives Differentially Suppress TFV and TAF Inhibition of HIV Infection and TFV-DP in Blood and Genital Tract CD4+ T cells [PDF]

Scientific Reports, 2017
HIV prevention research is focused on combining antiretrovirals (ARV) and progestin contraceptives to prevent HIV infection and pregnancy. The possibility that progestins compromise ARV anti-HIV activity prompted us to evaluate the effects of progestins ...
Zheng Shen, Mickey V Patel, Angela D M Kashuba   +2 more
exaly   +6 more sources

Hypo-osmolar Formulation of Tenofovir (TFV) Enema Promotes Uptake and Metabolism of TFV in Tissues, Leading to Prevention of SHIV/SIV Infection [PDF]

Antimicrobial Agents and Chemotherapy, 2018
ABSTRACT Oral preexposure prophylaxis (PrEP) has been approved for prophylaxis of HIV-1 transmission but is associated with high costs and issues of adherence. Protection from anal transmission of HIV using topical microbicides and methods congruent with sexual behavior offers the promise of improved adherence.
Sanjeev Gumber, Mark A Marzinke, Abhijit A Date   +2 more
exaly   +4 more sources

Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring [PDF]

Journal of Infectious Diseases, 2015
Self-reported adherence to pre-exposure prophylaxis (PrEP) has limitations, raising interest in pharmacologic monitoring. Drug concentrations in hair and dried blood spots (DBS) are used to assess long-term-exposure; hair shipment/storage occurs at room temperature.
Mónica Gandhi, David V Glidden, Albert Y Liu   +2 more
exaly   +7 more sources

Türkiye Tarım Sektöründe Toplam Faktör Verimliliği (TFV): 1961-2021 Döneminin Malmquist TFV Endeksiyle Analizi

Verimlilik Dergisi
Amaç: Bu çalışma, Türkiye tarım sektörünün 1961–2021 dönemindeki toplam faktör verimliliğini (TFV) ölçmek, teknik etkinlik değişimi (TEC) ile teknolojik etkinlik değişimi (TC) gibi TFV bileşenlerinin zaman içinde gösterdiği performansı etkileyen faktörleri analiz etmek amacıyla gerçekleştirilmiştir.
Nihat Küçük
exaly   +4 more sources

Differences in Local and Systemic TFV PK Among Premenopausal Versus Postmenopausal Women Exposed to TFV 1% Vaginal Gel [PDF]

Journal of Acquired Immune Deficiency Syndromes (1999), 2018
Objective: We describe and compare the local and systemic pharmacokinetics (PK) of tenofovir (TFV) and TFV-diphosphate (TFV-DP) in healthy premenopausal (PRE) and postmenopausal (POST) women using TFV 1% gel and correlate local PK with other mucosal end points. Methods: PRE (n = 20)
Andrea R Thurman, Neelima Chandra, Nazita Yousefieh   +2 more
exaly   +3 more sources

Discovery of Genetic Variants of the Kinases That Activate Tenofovir in a Compartment-specific Manner

EBioMedicine, 2015
Tenofovir (TFV) is used in combination with other antiretroviral drugs for human immunodeficiency virus (HIV) treatment and prevention. TFV requires two phosphorylation steps to become pharmacologically active; however, the kinases that activate TFV in ...
Julie M Lade, Elaine E To, Craig W Hendrix   +2 more
exaly   +3 more sources

Steady-state pharmacokinetics of plasma tenofovir alafenamide (TAF), tenofovir (TFV) and emtricitabine (FTC), and intracellular TFV-diphosphate and FTC-triphosphate in HIV-1 infected old Japanese patients treated with bictegravir/FTC/TAF

Global Health & Medicine, 2023
Emtricitabine (FTC) plus tenofovir alafenamide (TAF) has demonstrated efficacy and safety for pre-exposure prophylaxis (PrEP) to prevent HIV-1 infection. We measured the plasma PK of FTC, tenofovir (TFV), and TAF in a steady-state pharmacokinetic (PK) study of bictegravir/FTC/TAF in HIV-1-infected patients.
Kiyoto Tsuchiya, Akira Kawashima, Koji Watanabe   +2 more
exaly   +3 more sources

Targeting SIRT-1/AMPK/Nrf2 Signaling Pathway by Tenofovir Protected Against Cyclophosphamide-Induced Nephrotoxicity and Cardiotoxicity in Rats [PDF]

Pharmaceutics
Background/Objectives: Cyclophosphamide (CYC) is a commonly used alkylating agent for treating various cancers and autoimmune disorders. However, its use is often hampered by serious side effects, affecting multiple organs.
Yousef S. Alresheedi, Omnia A. Nour, Manar A. Nader, Marwa S. Zaghloul   +3 more
doaj   +2 more sources

Adherence thresholds for emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis against HIV acquisition in cisgender women: A randomized directly observed dosing study. [PDF]

PLoS Medicine
BackgroundOral emtricitabine/tenofovir disoproxil fumarate (F/TDF) preexposure prophylaxis (PrEP) effectiveness against HIV acquisition highly depends on adherence.
Kenneth K Mugwanya, Matilda Saina, Nelly R Mugo, Samantha MaWhinney, Mary Morrow, Torin T Schaafsma, Deborah Donnell, David V Glidden, Kenneth Ngure, Clare E Brown, Elena A Rechkina, Bhavna H Chohan, Linxuan Wu, Elex Hill, Eric Koome, Nina Akelo, Sarah Mbaire, Susan A Morrison, Mary Kibatha, Irene Njeru, Marianne Muriithi, Corwin Coppinger, Lane Bushman, Jared M Baeten, Peter L Anderson, Women Benchmark Study Team   +25 more
doaj   +2 more sources

Cost and clinical flow of point‐of‐care urine tenofovir testing for treatment monitoring among people living with HIV initiating ART in South Africa [PDF]

Journal of the International AIDS Society
Introduction Point‐of‐care (POC) urine tenofovir (TFV) tests can provide timely information regarding antiretroviral therapy (ART) adherence to support management of HIV treatment in clinics.
Melody Wang, Pravikrishnen Moodley, Mlungisi Khanyile, Elliot Bulo, Makhosazane Zondi, Keshani Naidoo, Yukteshwar Sookrajh, Jienchi Dorward, Monica Gandhi, Nigel Garrett, Paul K. Drain, Monisha Sharma   +11 more
doaj   +2 more sources